News | February 02, 2026
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Subscribe To Our Newsletter & Stay Updated
